Quality Risk Management (QRM) under ICH Q9(R1): Advanced Implementation Strategies, Regulatory Perspectives, and Lifecycle Integration in Pharmaceutical Manufacturing

Quality Risk Management (QRM) has evolved from a compliance formality into a strategic, science-based framework governing pharmaceutical quality across the product lifecycle. Anchored in ICH Q9 (2005) and its 2023 revision ICH Q9(R1), QRM provides a systematic process for identifying, assessing, controlling, communicating, and reviewing risks to drug product quality and patient safety. This review examines the foundational principles, global regulatory frameworks, key amendments introduced by Q9(R1), risk assessment methodologies, lifecycle integration with ICH Q10 and Q12, comparative QRM in sterile and non-sterile manufacturing, digital transformation including artificial intelligence and predictive analytics, major industry failure case studies, and regulatory inspection trends from 2020 to 2025. Key themes include the shift from subjective scoring to evidence-based risk assessment, the principle of proportionality in formality, recognition of product availability as a patient safety concern, and the emergence of hybrid quantitative-qualitative risk models supported by digital quality systems. Regulatory inspection analysis highlights persistent systemic gaps in data integrity, change management risk assessment, supplier oversight, and operational connectivity of risk outputs. The review concludes by identifying research gaps in AI governance, supply chain risk intelligence, biologics risk profiling, and patient-centered risk metrics. QRM under ICH Q9(R1) is positioned as an indispensable strategic pillar for patient protection, regulatory flexibility, and continuous improvement throughout the pharmaceutical product lifecycle.